

PERSONAL INFORMATION

Silvia Martina Ferrari

📍 P.zza del Mercato, 2 – 56043 Fauglia (PI)

☎ +39-347-8929579

✉ silviamartinaferrari@gmail.com

✉ silvia.ferrari@unipi.it

Sex: Female; Date of birth: 12-12-1978; Nationality: Italian.

Work experience

February 2007 - till nowadays	Nutritionist (freelance activity)
September 2, 2019 – till nowadays	Researcher Type Junior (RTD-A), at the Department of Clinical and Experimental Medicine, University of Pisa
February 1, 2018 – July 31, 2019	Research Scholarship entitled “Effetti sulla vitalità e meccanismi di apoptosi di alcuni farmaci antitumorali di nuova sintesi nel carcinoma papillare tiroideo” at the Department of Clinical and Experimental Medicine, University of Pisa
June 8, 2017 – December 31, 2017	Research Scholarship entitled “Valutazione della proliferazione dopo trattamento con vari agenti immunomodulanti di colture cellulari primarie umane di fibroblasti ottenuti da pazienti con Sclerodermia e fibroblasti retroorbitari da pazienti con Oftalmopatia Basedowiana” at the Department of Clinical and Experimental Medicine, University of Pisa
February 1, 2017 – May 31, 2017	Research Scholarship entitled “Valutazione della secrezione di chemochine e citochine dopo trattamento con vari agenti immunomodulanti di colture cellulari primarie umane di fibroblasti e mioblasti ottenuti da pazienti con Oftalmopatia Basedowiana” at the Department of Clinical and Experimental Medicine, University of Pisa
February 1, 2016 – January 31, 2017	Research Fellowship entitled “Valutazione della risposta immune Th1/Th2 e della secrezione di chemochine in pazienti con crioglobulinemia mista HCV-associata e sclerodermia, trattati con farmaci biologici” at the Dipartimento Integrato di Medicina e Specialità Mediche, University of Modena & Reggio Emilia
December 1, 2007- December 31, 2015	Research Fellowship entitled “Studio della risposta immune Th1/Th2 e delle chemochine CXC/CCL2 in pazienti con infezione da HCV complicata da crioglobulinemia mista (CM) e/o tireopatie autoimmuni (AITD) ed in pazienti con connettiviti sistemiche” at the Dipartimento Integrato di Medicina e Specialità Mediche, University of Modena & Reggio Emilia

- August 1, 2007- November 30, 2007 Research Fellowship entitled “Coinvolgimento della risposta immune Th1 e delle chemochine CXC nell’infezione da HCV in pazienti con crioglobulinemia mista (CM) e tireopatie autoimmuni (AITD)” at the Dipartimento Integrato di Medicine e Specialità Mediche, University of Modena & Reggio Emilia
- April 17, 2006 - November 16, 2006 Work Contract on “Effetti della 3,5-T2 su cellule tiroidee umane e adipociti in coltura”, at the Department of Internal Medicine, University of Pisa
- October 2005-April 2006 Research Scholarship entitled “Effetti della 3,5-T2 su cellule tiroidee umane e adipociti in coltura”, at the Department of Internal Medicine, University of Pisa
- October 2004-October 2005 Research Scholarship entitled “Modulazione della funzione cellulare da parte degli ormoni tiroidei (T3 e 3,5-T2) in tireociti e adipociti umani primari, e cellule beta-insulari” at the Department of Internal Medicine, University of Pisa
- April 2004-October 2004 Research Scholarship entitled “Alterazioni metaboliche e iodotironine” at the Department of Internal Medicine, University of Pisa
- April 2003-April 2004 Research Scholarship entitled “Valutazione degli effetti metabolici ed ormonali della 3,5-T2” at the Department of Internal Medicine, University of Pisa

Education and training

- October 2018 Suitable for: seconda fascia (Associate Professor):
- 06/D2 endocrinologia, nefrologia, scienze alimentazione, etc. -Abilitazione Scientifica Nazionale 2016-2018
- 06/N1 scienze delle professioni sanitarie e delle tecnologie mediche applicate – Abilitazione Scientifica Nazionale 2016-2018
- July 16, 2007 Post-graduate Specialization in Clinical Pathology, at the University of Pisa
- October 17, 2002 Degree in Biological Sciences, *cum laude*, at the University of Pisa

Personal skills and competences

Mother tongue(s) Italian

Other language(s)	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	B2	B2	B2	B2	B2

(*) Common European Framework of Reference for Languages

Social skills and competences	Good ability in public relation and work group
Technical skills and competences	Laboratory assay: Western Blot, ELISA, IRMA, RIA, cell cultures
Computer skills and competences	Good ability in use of Windows and Macintosh in particular suite Office.
Driving licence	B
Other Statements	She serves as an Editorial Board Member and is Reviewer of many scientific International journals.
Courses	Participation at Course ECDL-IT Security – Specialized Level (on February 13th, 2016) Participation at ICH-GCPs training (on January 05th, 2018 and March 11th, 2020) Participation at IATA, Infectious Substances and Dry Ice (2018) (on January 22 nd , 2019)
Scientific Activity	Participation as Biologist to the clinical study entitled “A phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects with Active Thyroid Eye Disease” at the Department of Clinical and Experimental Medicine, University of Pisa Participation as Biologist to the clinical study entitled “Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects with Thyroid Eye Disease” at the Department of Clinical and Experimental Medicine, University of Pisa

List of publications

1. Corti A, Ferrari SM, Lazzarotti A, Del Corso A, Mura U, Casini AF, Paolicchi A. UV light increases vitamin C uptake by bovine lens epithelial cells. *Mol Vis*. 2004 Aug 6;10:533-6.
2. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, Ferrannini E, Serio M. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. *J Clin Endocrinol Metab*. 2004 Nov;89(11):5496-5499.
3. Santini E, Fallahi P, Ferrari SM, Masoni A, Antonelli A, Ferrannini E. Effect of PPAR-gamma activation and inhibition on glucose-stimulated insulin release in INS-1e cells. *Diabetes*. 2004 Dec;53 Suppl 3:S79-83.
4. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Paolicchi A, Ferrannini E, Serio M. Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. *Eur J Endocrinol*. 2005 Feb;152(2):171-177.
5. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Ferrannini E, Serio M. Age-dependent changes in CXC chemokine ligand 10 serum levels in euthyroid subjects. *J Interferon Cytokine Res*. 2005 Sep;25(9):547-552.
6. Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Goglia F, Ferrannini E. Hepatitis C virus infection: evidence for an association with type 2 diabetes. *Diabetes Care*. 2005 Oct;28(10):2548-2550.
7. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Ghinoi A, Mascia MT, Ferrannini E. Extrahepatic manifestations of hepatitis C virus: the thyroid disorders. *Recenti Prog Med*. 2005 Jul-Aug;96(7-8):370-381.
8. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Serio M, Ferrannini E. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. *J Clin Endocrinol Metab*. 2006 Feb;91(2):614-620.
9. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Barani L, Ferrannini E, Serio M. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. *Clin Endocrinol (Oxf)*. 2006 Feb;64(2):189-195.
10. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, Grosso M, Ferrannini E, Serio M. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. *Eur J Endocrinol*. 2006 May;154(5):651-658.
11. Antonelli A, Rotondi M, Fallahi P, Ferrari SM, Paolicchi A, Romagnani P, Serio M, Ferrannini E. Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing. *Cytokine*. 2006 Apr;34(1-2):32-38.
12. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M, Miccoli P. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. *Br J Surg*. 2006 Oct;93(10):1226-1231.
13. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Ghinoi A, Rotondi M, Ferrannini E. Thyroid disorders in chronic hepatitis C virus infection. *Thyroid*. 2006 Jun;16(6):563-572.
14. Antonelli A, Fazzi P, Fallahi P, Ferrari SM, Ferrannini E. Prevalence of hypothyroidism and Graves disease in sarcoidosis. *Chest*. 2006 Aug;130(2):526-532.
15. Antonelli A, Delle Sedie A, Fallahi P, Ferrari SM, Maccheroni M, Ferrannini E, Bombardieri S, Riente L. High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis. *J Rheumatol*. 2006 Oct;33(10):2026-2028.
16. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Goglia F, Ferrannini E. Hepatitis C Virus Infection: Evidence for an Association With Type 2 Diabetes: Response to Skowronski et al. *Diabetes Care*. 2006 March;29(3):751.
17. Antonelli A, Miccoli P, Fallahi P, Ferrari SM, Grosso M, Boni G, Berti P. Thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma in children. *Surgery*. 2006 Dec;140(6):1035-1041; discussion 1041-1042.
18. Antonelli A, Rotondi M, Fallahi P, Grosso M, Boni G, Ferrari SM, Romagnani P, Serio M, Mariani G, Ferrannini E. Iodine-131 Given for Therapeutic Purposes Modulates Differently Interferon-gamma-Inducible alpha-Chemokine CXCL10 Serum Levels in Patients with Active Graves' Disease or Toxic Nodular Goiter. *J Clin Endocrinol Metab*. 2007 Apr;92(4):1485-1490.
19. Antonelli A, Ferri C, Fallahi P, Cazzato M, Ferrari SM, Sebastiani M, Ferrannini E. Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis. *Eur J Endocrinol*. 2007 Apr;156(4):431-437.
20. Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Barani L, Marchi S, Ferrannini E. Thyroid Cancer in HCV-Related Chronic Hepatitis Patients: A Case-Control Study. *Thyroid*. 2007 May;17(5):447-451.
21. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Giuggioli D, Colaci M, Manfredi A, Frascerra S, Franzoni F, Galetta F, Ferrannini E. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis--a longitudinal study. *Rheumatology (Oxford)*. 2008 Jan;47(1):45-49.
22. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, Ghiadoni L, Serio M, Taddei S, Ferrannini E. High serum levels of CXC chemokine ligand 10 in untreated essential hypertension. *J Hum Hypertens*. 2008 Aug;22(8):579-581.
23. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Sebastiani M, Franzoni F, Galetta F, Ferrannini E. High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. *Cytokine*. 2008 Apr;42(1):137-143.
24. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Marchetti I, Ugolini C, Basolo F, Miccoli P, Ferrannini E. Evaluation

of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. *Eur J Endocrinol*. 2008 Sep;159(3):283-291.

25. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Barani L, Marchetti I, Ferrannini E, Miccoli P. Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests. *Clin Endocrinol (Oxf)*. 2008 Jul;69(1):148-152.

26. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Carpi A, Nicolini A, Ferrannini E. Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis. *Metabolism*. 2008 Sep;57(9):1270-1277.

27. Antonelli A, Fallahi P, Ferrari SM, Carpi A, Berti P, Materazzi G, Minuto M, Guastalli M, Miccoli P. Dedifferentiated thyroid cancer: A therapeutic challenge. *Biomed Pharmacother*. 2008 Oct;62(8):559-563.

28. Antonelli A, Ferri C, Ferrari SM, Colaci M, Fallahi P. Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. *Autoimmun Rev*. 2008 Oct;8(1):18-23.

29. Antonelli A, Ferri C, Fallahi P, Colaci M, Giuggioli D, Ferrari SM, Frascerra S, Franzoni F, Galetta F, Ferrannini E. Th1 and Th2 Chemokine Serum Levels in Systemic Sclerosis in the Presence or Absence of Autoimmune Thyroiditis. *J Rheumatol*. 2008 Sep;35(9):1809-1811.

30. Antonelli A, Fallahi P, Tolari S, Ferrari SM, Ferrannini E. Thyroid-associated ophthalmopathy and TSH receptor autoantibodies in nonmetastatic thyroid cancer after total thyroidectomy. *Am J Med Sci*. 2008 Sep;336(3):288-290.

31. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Sebastiani M, Ferrari D, Giunti M, Frascerra S, Tolari S, Franzoni F, Galetta F, Marchi S, Ferrannini E. High Values of CXCL10 Serum Levels in Mixed Cryoglobulinemia Associated With Hepatitis C Infection. *Am J Gastroenterol*. 2008 Oct;103(10):2488-2494.

32. Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, Riente L, Ferrannini E. High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis. *Autoimmunity*. 2008 Nov;41(7):537-542.

33. Antonelli A, Fallahi P, Ferrari SM, Pupilli C, d'Annunzio G, Lorini R, Vanelli M, Ferrannini E. Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study. *Diabet Med*. 2008 Nov;25(11):1349-1353.

34. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Ghiri E, Carpi A, Nicolini A, Miccoli P. Treatment of Anaplastic Thyroid Cancer: Is there a Role for PPARgamma Agonists? *Recent Patents on Endocrine, Metabolic & Immune Drug Discovery*. 2008 Nov;2(3): 194-199.

35. Fallahi P, Ferri C, Ferrari SM, Pampana A, Sansonno D, Antonelli A. The emerging extrahepatic manifestations of hepatitis C virus infection in chronic hepatitis and mixed cryoglobulinemia. *Hepatitis Monthly*. 2008; 8(3): 207-211.

36. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Franzoni F, Galetta F, Zignego AL, Ferrannini E. CXCL10 and CCL2 serum levels in patients with mixed cryoglobulinaemia and hepatitis C. *Dig Liver Dis*. 2009 Jan;41(1):42-48.

37. Antonelli A, Fazzi P, Fallahi P, Ferrari SM, Grosso M, Boni G, Ferrannini E, Mariani G. Thyroid uptake of (67)Ga-citrate is associated with thyroid autoimmunity and hypothyroidism in patients with sarcoidosis. *Eur J Nucl Med Mol Imaging*. 2009 Jan;36(1):137-143.

38. Antonelli A, Ferri C, Ferrari SM, Colaci M, Sansonno D, Fallahi P. Endocrine manifestations of hepatitis C virus infection. *Nat Clin Pract Endocrinol Metab*. 2009 Jan;5(1):26-34.

39. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Minuto M, Giannini R, Marchetti I, Barani L, Basolo F, Ferrannini E, Miccoli P. Thiazolidinediones and antiproliferatives in primary human anaplastic thyroid cancer cells. *Clin Endocrinol (Oxf)*. 2009 Jun;70(6):946-953.

40. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Pampana A, Panicucci E, Carpi A, Nicolini A, Ferrannini E. CXCL10 and CCL2 chemokine serum levels in patients with hepatitis C associated with autoimmune thyroiditis. *J Interferon Cytokine Res*. 2009 Jun;29(6):345-51.

41. Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, Riente L, Ferrannini E. High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthritis. *Clin Exp Rheumatol*. 2009 Jan-Feb;27(1):22-27.

42. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Santini E, Franceschini SS, Ferrannini E. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. *J Clin Endocrinol Metab*. 2009 May;94(5):1803-1809.

43. Antonelli A, Ferri C, Ferrari SM, Ghiri E, Marchi S, Colaci M, Bruschi F, Fallahi P. High interleukin-6 and tumor necrosis factor-alpha serum levels in hepatitis C infection associated or not with mixed cryoglobulinemia. *Clin Rheumatol*. 2009 Oct;28(10):1179-1185.

44. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Piaggi S, Gelmini S, Lupi C, Minuto M, Berti P, Benvenga S, Basolo F, Orlando C, Miccoli P. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists. *Endocr Relat Cancer*. 2009 Dec;16(4):1299-1311.

45. Antonelli A, Ferri C, Ferrari SM, Galetta F, Franzoni F, Santoro G, De Marco S, Ghiri E, Fallahi P. High circulating N-terminal pro-brain natriuretic peptide and tumor necrosis factor-alpha in mixed cryoglobulinemia. *World J Gastroenterol*. 2009

Oct 28;15(40):5074-5079.

46. Antonelli A, Ferri C, Ferrari SM, Ghiri E, Galetta F, Franzoni F, Santoro G, Fallahi P. High circulating levels of N-terminal pro-brain natriuretic peptide and interleukin 6 in patients with mixed cryoglobulinemia. *J Med Virol.* 2010 Feb;82(2):297-303.
47. Antonelli A, Fallahi P, Mosca M, Ferrari SM, Ruffilli I, Corti A, Panicucci E, Neri R, Bombardieri S. Prevalence of thyroid dysfunctions in systemic lupus erythematosus. *Metabolism.* 2010 Jun;59(6):896-900.
48. Antonelli A, Ferri C, Ferrari SM, Colaci M, Sebastiani M, Zignego AL, Ghiri E, Goglia F, Fallahi P. High levels of circulating N-terminal pro-brain natriuretic peptide in patients with hepatitis C. *J Viral Hepat.* 2010 Dec;17(12):851-3.
49. Antonelli A, Ferri C, Ferrari SM, Ghiri E, Goglia F, Pampiana A, Bruschi F, Fallahi P. Serum levels of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor alpha in mixed cryoglobulinemia. *Arthritis Rheum.* 2009 Dec;60(12):3841-3847.
50. Antonelli A, Ferri C, Ferrari SM, Ghiri E, Marchi S, Sebastiani M, Fallahi P. Serum Concentrations of Interleukin 1{beta}, CXCL10, and Interferon-{\gamma} in Mixed Cryoglobulinemia Associated with Hepatitis C Infection. *J Rheumatol.* 2010 Jan;37(1):91-97.
51. Antonelli A, Mosca M, Fallahi P, Neri R, Ferrari SM, D'Ascanio A, Ghiri E, Carli L, Miccoli P, Bombardieri S. Thyroid Cancer in Systemic Lupus Erythematosus: A Case-Control Study. *J Clin Endocrinol Metab.* 2010 Jan;95(1):314-318.
52. Antonelli A, Ferrari SM, Fallahi P, Ghiri E, Crescioli C, Romagnani P, Vitti P, Serio M, Ferrannini E. Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: Modulation by peroxisome proliferator-activated receptor-gamma agonists. *Cytokine.* 2010 Jun;50(3):260-267.
53. Antonelli A, Ferri C, Ferrari SM, Marchi S, De Bortoli N, Sansonno D, Chiavacci C, Ferrannini E, Fallahi P. N-Terminal Pro-Brain Natriuretic Peptide and Tumor Necrosis Factor-alpha Both Are Increased in Patients With Hepatitis C. *J Interferon Cytokine Res.* 2010 May;30(5):359-363.
54. Antonelli A, Ferri C, Ferrari SM, Sebastiani M, Colaci M, Ruffilli I, Fallahi P. New targeted molecular therapies for dedifferentiated thyroid cancer. *J Oncol.* 2010;2010:921682.
55. Antonelli A, Ferri C, Ferrari SM, Colaci M, Giuggioli D, Fallahi P. Induction of CXCL10 secretion by interferon-gamma and tumour necrosis factor-alpha and its inhibition by peroxisome proliferator-activated receptor-gamma agonists in cultured scleroderma fibroblasts. *Br J Dermatol.* 2010 Sep;163(3):650-1.
56. Antonelli A, Ferrari SM, Frascerra S, Pupilli C, Mancusi C, Metelli MR, Orlando C, Ferrannini E, Fallahi P. CXCL9 and CXCL11 Chemokines Modulation by Peroxisome Proliferator-Activated Receptor-{\alpha} Agonists Secretion in Graves' and Normal Thyrocytes. *J Clin Endocrinol Metab.* 2010 Dec;95(12):E413-20.
57. Antonelli A, Ferri C, Ferrari SM, De Marco S, Di Domenicantonio A, Centanni M, Pupilli C, Villa E, Menichetti F, Fallahi P. Interleukin-1 β , C-X-C Motif Ligand 10, and Interferon-Gamma Serum Levels in Mixed Cryoglobulinemia With or Without Autoimmune Thyroiditis. *J Interferon Cytokine Res.* 2010 Nov;30(11):835-42.
58. Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Fioravanti A, Sartini S, Minuto M, Piaggi S, Corti A, Ali G, Berti P, Fontanini G, Danesi R, Da Settimo F, Miccoli P. Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. *J Clin Endocrinol Metab.* 2011 Feb;96(2):E288-96.
59. Antonelli A, Ferri C, Ferrari SM, Di Domenicantonio A, Ferrari P, Pupilli C, Nicolini A, Zignego AL, Marchi S, Fallahi P. The presence of autoimmune thyroiditis in mixed cryoglobulinemia patients is associated with high levels of circulating Interleukin-6, but not of Tumor Necrosis Factor-alpha. *Clin Exp Rheumatol.* 2011 an-Feb;29(1 Suppl 64):S17-22.
60. Antonelli A, Ferrari SM, Fallahi P, Minuto M, Corrado A, Bruno R, Miccoli P. Medullary thyroid cancer: New targeted molecular therapies. *Recent Patents on Endocrine, Metabolic and Immune Drug Discovery* 2010;4 (1):10-14.
61. Antonelli A, Ferrari SM, Fallahi P, Piaggi S, Paolicchi A, Franceschini SS, Salvi M, Ferrannini E. Cytokines (interferon- γ and tumor necrosis factor- α)-induced nuclear factor- κ B activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. *Metabolism.* 2011 Feb;60(2):277-83.
62. Antonelli A, Ferrari SM, Frascerra S, Corrado A, Pupilli C, Bernini G, Benvenga S, Ferrannini E, Fallahi P. Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease. *Exp Cell Res.* 2011 Jul 1;317(11):1527-33.
63. Antonelli A, Ferrari SM, Frascerra S, Di Domenicantonio A, Nicolini A, Ferrari P, Ferrannini E, Fallahi P. Increase of Circulating CXCL9 and CXCL11 Associated with Euthyroid or Subclinically Hypothyroid Autoimmune Thyroiditis. *J Clin Endocrinol Metab.* 2011 Jun;96(6):1859-63.
64. Antonelli A, Ferrari SM, Frascerra S, Galetta F, Franzoni F, Corrado A, Miccoli M, Benvenga S, Paolicchi A, Ferrannini E, Fallahi P. Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. *Cytokine.* 2011 Aug;55(2):288-93.
65. Antonelli A, Ferri C, Ferrari S, Mancusi C, Colaci M, Sebastiani M, Fallahi P. IFN- γ and TNF- α induce a different modulation of interleukin-6 in systemic sclerosis fibroblasts compared to healthy controls. *Scand J Rheumatol.* 2011 Nov;40(6):453-6.
66. Antonelli A, Ferri C, Ferrari SM, Ruffilli I, Colaci M, Frascerra S, Miccoli M, Franzoni F, Galetta F, Fallahi P. High Serum Levels of CXCL11 in Mixed Cryoglobulinemia Are Associated with Increased Circulating Levels of Interferon-{\gamma}. *J Rheumatol.* 2011 Sep;38(9):1947-52.

67. Antonelli A, Miccoli P, Materazzi G, Minuto M, Fallahi P, Ferrari SM, Berti P. The Role of Total Thyroidectomy in the Initial Treatment of Well-differentiated Follicular-cell-derived Thyroid Carcinomas. *European Endocrinology - Thyroid Disorders*, 2011;6(1):73-6.
68. Antonelli A, Fallahi P, Ulisse S, Ferrari SM, Minuto M, Saraceno G, Santini F, Mazzi V, D'Armiento M, Miccoli P. New Targeted Therapies for Anaplastic Thyroid Cancer. *Anticancer Agents Med Chem*. 2012 Jan 1;12(1):87-93.
69. Antonelli A, Ferrari SM, Frascerra S, Ruffilli I, Gelmini S, Minuto M, Pupilli C, Miccoli P, Sellari-Franceschini S, Ferrannini E, Fallahi P. Peroxisome proliferator-activated receptor- α agonists modulate CXCL9 and CXCL11 chemokines in Graves' ophthalmopathy fibroblasts and preadipocytes. *Mol Cell Endocrinol*. 2012 Feb 26;349(2):255-61.
70. Antonelli A, Ferri C, Ferrari SM, Frascerra S, Ruffilli I, Caponi L, Ulisse S, Miccoli M, Miccoli P, Fallahi P. High Levels of Circulating Chemokine (C-X-C motif) Ligand 11 Are Associated with Euthyroid or Subclinically Hypothyroid Autoimmune Thyroiditis and with Chemokine (C-X-C Motif) Ligand 10. *J Interferon Cytokine Res*. 2012 Feb;32(2):74-80.
71. Antonelli A, Fallahi P, Ferrari SM, Sebastiani M, Manfredi A, Mazzi V, Fabiani S, Centanni M, Marchi S, Ferri C. Circulating CXCL11 and CXCL10 are increased in hepatitis C-associated cryoglobulinemia in the presence of autoimmune thyroiditis. *Mod Rheumatol*. 2012 Sep;22(5):659-67.
72. Antonelli A, Fallahi P, Ferrari SM, Di Domenicantonio A, Moreno M, Lanni A, Goglia F. 3,5-diiodo-L-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects. *J Biol Regul Homeost Agents*. 2011 Oct-Dec;25(4):655-60.
73. Antonelli A, Fallahi P, Ferrari SM, Mancusi C, Colaci M, Santarpia L, Ferri C. RET TKI: Potential Role in Thyroid Cancers. *Curr Oncol Rep*. 2012 Apr;14(2):97-104.
74. Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Ruffilli I, Di Domenicantonio A, Fioravanti A, Sartini S, Minuto M, Piaggi S, Corti A, Ali G, Di Desidero T, Berti P, Fontanini G, Danesi R, Da Settimo F, Miccoli P. CLM94, a Novel Cyclic Amide with Anti-VEGFR-2 and Antiangiogenic Properties, Is Active against Primary Anaplastic Thyroid Cancer in Vitro and in Vivo. *J Clin Endocrinol Metab*. 2012 Apr;97(4):E528-36.
75. Antonelli A, Fallahi P, Ferrari SM, Ruffilli I, Santini F, Minuto M, Galleri D, Miccoli P. New targeted therapies for thyroid cancer. *Current Genomics*, 2011; 12:626-631.
76. Antonelli A, Ferrari SM, Frascerra S, Ruffilli I, Pupilli C, Bernini G, Sellari Franceschini S, Gelmini S, Ferrannini E, Fallahi P. β (CCL2) and α (CXCL10) chemokines modulation by cytokines and by peroxisome proliferator activated receptor- α agonists in Graves' ophthalmopathy. *J Endocrinol*. 2012 May;213(2):183-91.
77. Antonelli A, Fallahi P, Ferrari SM, Giuggioli D, Colaci M, Di Domenicantonio A, Ferri C. Systemic Sclerosis Fibroblasts Show Specific Alterations of Interferon- γ and Tumor Necrosis Factor- α -induced Modulation of Interleukin 6 and Chemokine Ligand 2. *J Rheumatol*. 2012 May;39(5):979-85.
78. Fallahi P, Ferri C, Ferrari SM, Corrado A, Sansonno D, Antonelli A. Cytokines and HCV-Related Disorders. *Clin Dev Immunol*. 2012;2012:468107.
79. Antonelli A, Ferrari SM, Fallahi P, Piaggi S, Di Domenicantonio A, Galleri D, Santarpia L, Basolo F, Ferrannini E, Miccoli P. Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. *Cytokine*. 2012 Aug;59(2):218-22.
80. Antonelli A, Fallahi P, Ferrari SM, Ghiadoni L, Virdis A, Mancusi C, Centanni M, Taddei S, Ferrannini E. High serum levels of CXC (CXCL10) and CC (CCL2) chemokines in untreated essential hypertension. *Int J Immunopathol Pharmacol*. 2012 Apr-Jun;25(2):387-95.
81. Antonelli A, Ferri C, Ferrari SM, Di Domenicantonio A, Mancusi C, Marchi S, De Bortoli N, Metelli MR, Bruschi F, Fallahi P. Hepatitis C is associated with high levels of circulating N-terminal pro-brain natriuretic peptide and interleukin-6. *European Journal of Inflammation*. 2012 Jan-Apr;10(1):133-138.
82. Antonelli A, Fallahi P, Ferrari SM, Corrado A, Sebastiani M, Manfredi A, Frascerra S, Miccoli M, Zignego AL, Ferrannini E, Ferri C. Chemokine (CXC motif) ligand 9 serum levels in mixed cryoglobulinemia are associated with circulating levels of IFN- γ and TNF- α . *Clin Exp Rheumatol*. 2012 Jul 4; 30(6):864-70.
83. Antonelli A, Fallahi P, Ferrari SM, Frascerra S, Corrado A, Colaci M, Manfredi A, Maccheroni, M, Sansonno D, Zignego AL, Centanni M, Ferri C. Patients with mixed cryoglobulinemia and HCV infection, in presence or absence of autoimmune thyroiditis, have high serum levels of (CXC motif) ligand (CXCL)9 and CXCL11 chemokines. *European Journal of Inflammation*. 2012; 10(3):437-445.
84. Antonelli A, Ferri C, Ferrari SM, Colaci M, Ruffilli I, Sebastiani M, Fallahi P. Peroxisome proliferator-activated receptor γ agonists reduce cell proliferation and viability and increase apoptosis in SSc fibroblasts. *Br J Dermatol*. 2013 Jan;168(1):129-35.
85. Antonelli A, Ferrari SM, Mancusi C, Mazzi V, Pupilli C, Centanni M, Ferri C, Ferrannini E, Fallahi P. Interferon- α , - β and - γ induce CXCL11 secretion in human thyrocytes: Modulation by peroxisome proliferator-activated receptor γ agonists. *Immunobiology*. 2013 May;218(5):690-5.
86. Antonelli A, Fallahi P, Ferrari SM, Corrado A, Sebastiani M, Giuggioli D, Miccoli M, Zignego AL, Sansonno D, Marchi S, Ferri C. Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2. *Clin Rheumatol*. 2013 Aug;32(8):1147-54.
87. Antonelli A, Ferrari SM, Corrado A, Ferrannini E, Fallahi P. Increase of interferon- γ inducible α chemokine (C-X-C motif)

- ligand (CXCL)9 and CXCL11 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. *Thyroid*. 2013 Nov;23(11):1461-9.
88. Antonelli A, Fallahi P, Ferrari SM, Mancusi C, Giuggioli D, Colaci M, Ferri C. Incidence of thyroid disorders in systemic sclerosis: results from a longitudinal follow-up. *J Clin Endocrinol Metab*. 2013 Jul;98(7):E1198-202.
89. Fallahi P, Ferrari SM, Santini F, Corrado A, Materazzi G, Ulisse S, Miccoli P, Antonelli A. Sorafenib and Thyroid Cancer. *BioDrugs*. 2013 Dec;27(6):615-28.
90. Antonelli A, Fallahi P, Ferrari SM, Frascerra S, Mancusi C, Colaci M, Manfredi A, Sansonno D, Zignego AL, Ferri C. High circulating chemokines (C-X-C motif) ligand 9, and (C-X-C motif) ligand 11, in hepatitis C-associated cryoglobulinemia. *Int J Immunopathol Pharmacol*. 2013 Jan-Mar;26(1):49-57.
91. Antonelli A, Fallahi P, Ferrari SM, Colaci M, Giuggioli D, Saraceno G, Benvenga S, Ferri C. Increased CXCL9 Serum Levels in Hepatitis C-Related Mixed Cryoglobulinemia, with Autoimmune Thyroiditis, Associated with High Levels of CXCL10. *J Interferon Cytokine Res*. 2013 Dec;33(12):739-45.
92. Fallahi P, Ferrari SM, Giuggioli D, Corrado A, Fabiani S, Marchi S, Ferri C, Antonelli A. Mixed cryoglobulinemia and thyroid autoimmune disorders. *Clin Ter*. 2013 Jul-Aug;164(4):e337-41.
93. Ferrari SM, Fallahi P, Mancusi C, Colaci M, Manfredi A, Ferri C, Antonelli A. HCV-related autoimmune disorders in HCV chronic infection. *Clin Ter*. 2013 Jul-Aug;164(4):e305-12.
94. Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Corrado A, Fioravanti A, Sartini S, Orlandi P, Piaggi S, Corti A, Materazzi G, Galleri D, Ulisse S, Fontanini G, Danesi R, Da Settimo F, Miccoli P. CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo. *Mol Cell Endocrinol*. 2014 Aug 5;393(1-2):56-64.
95. Fallahi P, Ferrari SM, Vita R, Di Domenicantonio A, Corrado A, Benvenga S, Antonelli A. Thyroid dysfunctions induced by tyrosine kinase inhibitors. *Expert Opin Drug Saf*. 2014 Jun;13(6):723-33.
96. Corrado A, Ferrari SM, Ferri C, Ferrannini E, Antonelli A, Fallahi P. Type 1 diabetes and (C-X-C motif) ligand (CXCL) 10 chemokine. *Clin Ter*. 2014;165(2):e181-5.
97. Fallahi P, Ferrari SM, Giuggioli D, Manfredi A, Mancusi C, Fabiani S, Centanni M, Marchi S, Ferri C, Antonelli A. Thyroid involvement in hepatitis C - associated mixed cryoglobulinemia. *Hormones (Athens)*. 2014 Jan-Mar;13(1):16-23.
98. Antonelli A, Ferrari SM, Corrado A, Ferrannini E, Fallahi P. CXCR3, CXCL10 and type 1 diabetes. *Cytokine Growth Factor Rev*. 2014 Feb;25(1):57-65.
99. Antonelli A, Bocci G, Fallahi P, La Motta C, Ferrari SM, Mancusi C, Fioravanti A, Di Desidero T, Sartini S, Corti A, Piaggi S, Materazzi G, Spinelli C, Fontanini G, Danesi R, Da Settimo F, Miccoli P. CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. *J Clin Endocrinol Metab*. 2014 Apr;99(4):E572-81.
100. Ferrari SM, Antonelli A, Di Domenicantonio A, Manfredi A, Ferri C, Fallahi P. Modulatory Effects of Peroxisome Proliferator-Activated Receptor- γ on CXCR3 Chemokines. *Recent Pat Inflamm Allergy Drug Discov*. 2014;8(2):132-8.
101. Fallahi P, Ferrari SM, Corrado A, Giuggioli D, Ferri C, Antonelli A. Targeting Chemokine (C-X-C motif) Receptor 3 in Thyroid Autoimmunity. *Recent Pat Endocr Metab Immune Drug Discov*. 2014;8(2):95-101.
102. Fallahi P, Ferrari SM, Mazzi V, Vita R, Benvenga S, Antonelli A. Personalization of targeted therapy in advanced thyroid cancer. *Curr Genomics*. 2014 Jun;15(3):190-202.
103. Ruffilli I, Ferrari SM, Colaci M, Ferri C, Fallahi P, Antonelli A. IP-10 in Autoimmune Thyroiditis. *Horm Metab Res*. 2014 Aug;46(9):597-602.
104. Ruffilli I, Ferrari SM, Colaci M, Ferri C, Politti U, Antonelli A, Fallahi P. [CXCR3 and CXCL10 in autoimmune thyroiditis]. *Clin Ter*. 2014;165(3):e237-42.
105. Ferrari SM, Fallahi P, La Motta C, Bocci G, Corrado A, Materazzi G, Galleri D, Piaggi S, Danesi R, Da Settimo F, Miccoli P, Antonelli A. Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro. *Surgery*. 2014 Nov;156(5):1167-76.
106. Antonelli A, Ferrari SM, Corrado A, Franceschini SS, Gelmini S, Ferrannini E, Fallahi P. Extra-ocular muscle cells from patients with Graves' ophthalmopathy secrete α (CXCL10) and β (CCL2) chemokines under the influence of cytokines that are modulated by PPAR γ . *Autoimmun Rev*. 2014 Nov;13(11):1160-1166.
107. Antonelli A, Ferrari SM, Giuggioli D, Di Domenicantonio A, Ruffilli I, Corrado A, Fabiani S, Marchi S, Ferri C, Ferrannini E, Fallahi P. Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. *World J Diabetes*. 2014 Oct 15;5(5):586-600.
108. Corrado A, Mazzi V, Ferrari SM, Politti U, Giuggioli D, Antonelli A, Fallahi P, Ferri C. [Cryoglobulinemia and the α -chemokine IP-10.] *Clin Ter*. 2014 Jul-Aug;165(4):e317-e322.
109. Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. *Autoimmun Rev*. 2014 Mar;13(3):272-80.
110. Antonelli A, Ferrari SM, Ruffilli I, Fallahi P. Cytokines and HCV-related autoimmune disorders. *Immunol Res*. 2014 Dec;60(2-3):311-9.
111. Fallahi P, Ferrari SM, Politti U, Giuggioli D, Ferri C, Antonelli A. Autoimmune and neoplastic thyroid diseases associated with hepatitis C chronic infection. *Int J Endocrinol*. 2014;2014:935131.
112. Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. *Autoimmun Rev*.

2015 Feb;14(2):174-180.

113. Antonelli A, Ferrari SM, Fallahi P. The role of the Th1 chemokine CXCL10 in vitiligo. *Ann Transl Med.* 2015 May;3(Suppl 1):S16.
114. Fallahi P, Mazzi V, Vita R, Ferrari SM, Materazzi G, Galleri D, Benvenega S, Miccoli P, Antonelli A. New therapies for dedifferentiated papillary thyroid cancer. *Int J Mol Sci.* 2015 Mar 17;16(3):6153-82.
115. Ferrari SM, Fallahi P, Vita R, Antonelli A, Benvenega S. Peroxisome Proliferator-Activated Receptor- γ in Thyroid Autoimmunity. *PPAR Res.* 2015;2015:232818.
116. Mazzi V, Ferrari SM, Giuggioli D, Antonelli A, Ferri C, Fallahi P. Role of CXCL10 in cryoglobulinemia. *Clin Exp Rheumatol.* 2015 May-Jun;33(3):433-6.
117. Antonelli A, Ferri C, Ferrari SM, Di Domenicantonio A, Giuggioli D, Galleri D, Miccoli P, Fallahi P. Increased risk of papillary thyroid cancer in systemic sclerosis associated with autoimmune thyroiditis. *Rheumatology (Oxford).* 2016 Mar;55(3):480-4.
118. Ferrari SM, Ruffilli I, Colaci M, Antonelli A, Ferri C, Fallahi P. CXCL10 in psoriasis. *Adv Med Sci.* 2015 Sep;60(2):349-54.
119. Fallahi P, Ferrari SM, La Motta C, Materazzi G, Bocci G, Da Settimo F, Miccoli P, Antonelli A. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation. *Endocrine.* 2016 Jul;53(1):136-44.
120. Fallahi P, Di Bari F, Ferrari SM, Spisni R, Materazzi G, Miccoli P, Benvenega S, Antonelli A. Selective use of vandetanib in the treatment of thyroid cancer. *Drug Des Devel Ther.* 2015 Jul 3;9:3459-70.
121. Ferrari SM, Politti U, Spisni R, Materazzi G, Baldini E, Ulisse S, Miccoli P, Antonelli A, Fallahi P. Sorafenib in the treatment of thyroid cancer. *Expert Rev Anticancer Ther.* 2015 Aug;15(8):863-74.
122. Antonelli A, Fallahi P, Ulisse S, Ferrari SM, Mazzi V, Di Domenicantonio A, Miccoli P. Tyrosine kinase inhibitors for the therapy of anaplastic thyroid cancer. *International Journal of Endocrine Oncology.* 2015;2(2):135-142.
123. Ferrari SM, Fallahi P, Politti U, Materazzi G, Baldini E, Ulisse S, Miccoli P, Antonelli A. Molecular Targeted Therapies of Aggressive Thyroid Cancer. *Front Endocrinol (Lausanne).* 2015 Nov 20;6:176.
124. Fallahi P, Ferrari SM, Di Bari F, Materazzi G, Benvenega S, Miccoli P, Antonelli A. Cabozantinib in Thyroid Cancer. *Recent Pat Anticancer Drug Discov.* 2015;10(3):259-69.
125. Ferrari SM, Motta CL, Sartini S, Baldini E, Materazzi G, Politti U, Ruffilli I, Ulisse S, Miccoli P, Antonelli A, Fallahi P. Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer. *Mini Rev Med Chem.* 2016;16(2):86-93.
126. Fallahi P, Corrado A, Di Domenicantonio A, Frenzilli G, Antonelli A, Ferrari SM. CXCR3, CXCR5, CXCR6, and CXCR7 in Diabetes. *Curr Drug Targets.* 2016;17(5):515-9.
127. Ferrari SM, Materazzi G, Baldini E, Ulisse S, Miccoli P, Antonelli A, Fallahi P. Antineoplastic Effects of PPAR γ Agonists, with a Special Focus on Thyroid Cancer. *Curr Med Chem.* 2016;23(7):636-49.
128. Fallahi P, Ferrari SM, Antonelli A. Oral L-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: a prospective study. *Endocrine.* 2016 Jun;52(3):597-601.
129. Fallahi P, Ferrari SM, Elia G, Nasini F, Colaci M, Giuggioli D, Vita R, Benvenega S, Ferri C, Antonelli A. Novel Therapies for Thyroid Autoimmune Diseases. *Expert Rev Clin Pharmacol.* 2016 Jun;9(6):853-61.
130. Fallahi P, Ferrari SM, Ruffilli I, Antonelli A. Reversible normalisation of serum TSH levels in patients with autoimmune atrophic gastritis who received L-T4 in tablet form after switching to an oral liquid formulation: a case series. *BMC Gastroenterol.* 2016 Feb 24;16:22.
131. Fallahi P, Ferrari SM, Ruffilli I, Elia G, Giuggioli D, Colaci M, Ferri C, Antonelli A. Incidence of thyroid disorders in mixed cryoglobulinemia: Results from a longitudinal follow-up. *Autoimmun Rev.* 2016 Jul;15(7):747-51.
132. Fallahi P, Ferrari SM, Vita R, Benvenega S, Antonelli A. The role of human parvovirus B19 and hepatitis C virus in the development of thyroid disorders. *Rev Endocr Metab Disord.* 2016 Dec;17(4):529-535.
133. Corrado A, Ferrari SM, Politti U, Mazzi V, Miccoli M, Materazzi G, Antonelli A, Ulisse S, Fallahi P, Miccoli P. Aggressive thyroid cancer: targeted therapy with sorafenib. *Minerva Endocrinol.* 2017 Mar;42(1):64-76.
134. Fallahi P, Ferrari SM, Giuggioli D, Sebastiani M, Colaci M, Ferri C, Antonelli A. Chemokines in the pathogenesis and as therapeutical markers and targets of HCV chronic infection, and HCV extrahepatic manifestations. *Curr Drug Targets* 2017;18(7):786-793.
135. Fallahi P, Ferrari SM, Camastra S, Politti U, Ruffilli I, Vita R, Navarra G, Benvenega S, Antonelli A. TSH Normalization in Bariatric Surgery Patients After the Switch from L-Thyroxine in Tablet to an Oral Liquid Formulation. *Obes Surg.* 2017 Jan;27(1):78-82.
136. Fallahi P, Ferrari SM, Ruffilli I, Ragusa F, Biricotti M, Materazzi G, Miccoli P, Antonelli A. Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update. *Expert Opin Drug Deliv.* 2017 May;14(5):647-655.
137. Fallahi P, Ferrari SM, Marchi S, De Bortoli N, Ruffilli I, Antonelli A. Patients with lactose intolerance absorb liquid levothyroxine better than tablet levothyroxine. *Endocrine.* 2017 Jul;57(1):175-178.
138. Fallahi P, Ferrari SM, Ruffilli I, Elia G, Biricotti M, Vita R, Benvenega S, Antonelli A. The association of other autoimmune diseases in patients with autoimmune thyroiditis: Review of the literature and report of a large series of patients. *Autoimmun*


Rev. 2016 Dec;15(12):1125-1128.

139. Fallahi P, Ferrari SM, Baldini E, Biricotti M, Ulisse S, Materazzi G, Miccoli P, Antonelli A. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer. *Expert Rev Anticancer Ther.* 2016 Nov;16(11):1109-1118.
140. Fallahi P, Ferrari SM, Antonelli A. IN PATIENTS WITH SUBCLINICAL HYPOTHYROIDISM WHILE IN THERAPY WITH TABLET L-T4, THE LIQUID L-T4 FORMULATION IS MORE EFFECTIVE IN RESTORING EUTHYROIDISM. *Endocr Pract.* 2017 Feb;23(2):170-174.
141. Fallahi P, Ferrari SM, Ruffilli I, Elia G, Miccoli M, Sedie AD, Riente L, Antonelli A. Increased incidence of autoimmune thyroid disorders in patients with psoriatic arthritis: a longitudinal follow-up study. *Immunol Res.* 2017 Jun;65(3):681-686.
142. Ferrari SM, Fallahi P, Antonelli A, Benvenega S. Environmental Issues in Thyroid Diseases. *Front Endocrinol (Lausanne).* 2017 Mar 20;8:50.
143. Antonelli A, Fallahi P, Di Bari F, Giuggioli D, Ferrari SM, Ferri C. Fatigue in patients with systemic sclerosis and hypothyroidism. A review of the literature and report of our experience. *Clin Exp Rheumatol.* 2017 Sep-Oct;35 Suppl 106(4):193-197.
144. Ferrari SM, Elia G, Virili C, Centanni M, Antonelli A, Fallahi P. Systemic Lupus Erythematosus and Thyroid Autoimmunity. *Front Endocrinol (Lausanne).* 2017 Jun 19;8:138.
145. Ruffilli I, Ragusa F, Benvenega S, Vita R, Antonelli A, Fallahi P, Ferrari SM. Psoriasis, Psoriatic Arthritis, and Thyroid Autoimmunity. *Front Endocrinol (Lausanne).* 2017 Jun 19;8:139.
146. Ferrari SM, Fallahi P, Santaguida G, Virili C, Ruffilli I, Ragusa F, Centanni M, Antonelli A. Circulating CXCL10 is increased in non-segmental vitiligo, in presence or absence of autoimmune thyroiditis. *Autoimmun Rev.* 2017 Sep;16(9):946-950.
147. Benvenega S, Vicchio T, Di Bari F, Vita R, Fallahi P, Ferrari SM, Catania S, Costa C, Antonelli A. Favorable effects of myo-inositol, selenomethionine or their combination on the hydrogen peroxide-induced oxidative stress of peripheral mononuclear cells from patients with Hashimoto's thyroiditis: preliminary in vitro studies. *Eur Rev Med Pharmacol Sci.* 2017 Jun;21(2 Suppl):89-101.
148. Ferrari SM, Fallahi P, Di Bari F, Vita R, Benvenega S, Antonelli A. Myo-inositol and selenium reduce the risk of developing overt hypothyroidism in patients with autoimmune thyroiditis. *Eur Rev Med Pharmacol Sci.* 2017 Jun;21(2 Suppl):36-42.
149. Ferri C, Colaci M, Fallahi P, Ferrari SM, Antonelli A, Giuggioli D. Thyroid Involvement in Hepatitis C Virus-Infected Patients with/without Mixed Cryoglobulinemia. *Front Endocrinol (Lausanne).* 2017 Jul 7;8:159.
150. Fazzi P, Fallahi P, Ferrari SM. Sarcoidosis and Thyroid Autoimmunity. *Front Endocrinol (Lausanne).* 2017 Aug 8;8:177.
151. Di Desidero T, Antonelli A, Orlandi P, Ferrari SM, Fioravanti A, Ali G, Fontanini G, Basolo F, Francia G, Bocci G. Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer. *Cancer Lett.* 2017 Dec 28;411:35-43.
152. Fallahi P, Ruffilli I, Giuggioli D, Colaci M, Ferrari SM, Antonelli A, Ferri C. Associations between Systemic Sclerosis and Thyroid Diseases. *Front Endocrinol (Lausanne).* 2017 Oct 3;8:266.
153. Ferrari SM, Centanni M, Virili C, Miccoli M, FerrariPaola P, Ruffilli I, Ragusa F, Antonelli A, Fallahi P. Sunitinib in the treatment of thyroid cancer. *Curr Med Chem.* 2017 Oct 6. doi: 10.2174/0929867324666171006165942. [Epub ahead of print]
154. Ferrari SM, Fallahi P, Ruffilli I, Elia G, Ragusa F, Paparo SR, Ulisse S, Baldini E, Giannini R, Miccoli P, Antonelli A, Basolo F. Molecular testing in the diagnosis of differentiated thyroid carcinomas. *Gland Surg.* 2018 Aug;7(Suppl 1):S19-S29.
155. Fallahi P, Ruffilli I, Elia G, Ragusa F, Ulisse S, Baldini E, Miccoli M, Materazzi G, Antonelli A, Ferrari SM. Novel treatment options for anaplastic thyroid cancer. *Expert Rev Endocrinol Metab.* 2017 Jul;12(4):279-288.
156. Fallahi P, Foddìs R, Elia G, Ragusa F, Patrizio A, Benvenega S, Cristaudo A, Antonelli A, Ferrari SM. CXCL8 and CXCL11 chemokine secretion in dermal fibroblasts is differentially modulated by vanadium pentoxide. *Mol Med Rep.* 2018 Aug;18(2):1798-1803.
157. Benvenega S, Capodicasa G, Perelli S, Ferrari SM, Fallahi P, Antonelli A. Increased Requirement of Replacement Doses of Levothyroxine Caused by Liver Cirrhosis. *Front Endocrinol (Lausanne).* 2018 Apr 18;9:150.
165. Fallahi P, Foddìs R, Elia G, Ragusa F, Patrizio A, Frenzilli G, Benvenega S, Cristaudo A, Antonelli A, Ferrari SM. Differential modulation by vanadium pentoxide of the secretion of CXCL8 and CXCL11 chemokines in thyroid cells. *Mol Med Rep.* 2018 May;17(5):7415-7420.
158. La Pietra V, Sartini S, Botta L, Antonelli A, Ferrari SM, Fallahi P, Moriconi A, Coviello V, Quattrini L, Ke YY, Hsing-Pang H, Da Settimo F, Novellino E, La Motta C, Marinelli L. Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors. *Eur J Med Chem.* 2018 Apr 25;150:491-505.
159. Fallahi P, Foddìs R, Elia G, Ragusa F, Patrizio A, Guglielmi G, Frenzilli G, Benvenega S, Cristaudo A, Antonelli A, Ferrari SM. Induction of Th1 chemokine secretion in dermal fibroblasts by vanadium pentoxide. *Mol Med Rep.* 2018 May;17(5):6914-6918.
160. Fallahi P, Foddìs R, Elia G, Ragusa F, Patrizio A, Benvenega S, Cristaudo A, Antonelli A, Ferrari SM. Vanadium pentoxide induces the secretion of CXCL9 and CXCL10 chemokines in thyroid cells. *Oncol Rep.* 2018 May;39(5):2422-2426.
161. Ferrari SM, Bocci G, Di Desidero T, Ruffilli I, Elia G, Ragusa F, Fioravanti A, Orlandi P, Paparo SR, Patrizio A, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, Antonelli A, Fallahi P. Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo. *Oncol Rep.* 2018 May;39(5):2306-2314.

162. Ferrari SM, Bocci G, Di Desidero T, Elia G, Ruffilli I, Ragusa F, Orlandi P, Paparo SR, Patrizio A, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, Antonelli A, Fallahi P. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. *Oncol Rep.* 2018 May;39(5):2225-2234.
163. Ferrari SM, Ruffilli I, Centanni M, Virili C, Materazzi G, Alexopoulou M, Miccoli M, Antonelli A, Fallahi P. Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied. *Recent Pat Anticancer Drug Discov.* 2018;13(2):201-208.
164. Fabiani S, Fallahi P, Ferrari SM, Miccoli M, Antonelli A. Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature. *Rev Endocr Metab Disord.* 2018 Dec;19(4):405-420.
165. Antonelli A, Ferrari SM, Fallahi P. Current and future immunotherapies for thyroid cancer. *Expert Rev Anticancer Ther.* 2018 Feb;18(2):149-159.
166. Ferrari SM, La Motta C, Elia G, Ragusa F, Ruffilli I, Quattrini L, Paparo SR, Piaggi S, Patrizio A, Ulisse S, Baldini E, Materazzi G, Fallahi P, Antonelli A. Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration. *Front Endocrinol (Lausanne).* 2018 Dec;9:764.
167. Ferrari SM, Fallahi P, Ruffilli I, Elia G, Ragusa F, Benvenga S, Antonelli A. The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): Review of the literature and report of a large series. *Autoimmun Rev.* 2019 Mar;18(3):287-292.
168. Ferrari SM, Ragusa F, Paparo SR, Nasini F, Nardi M, Franceschini SS, Fallahi P, Antonelli A. Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy. *Autoimmun Rev.* 2019 Jul;18(7):673-678.
169. Ferrari SM, Fallahi P, Elia G, Ragusa F, Ruffilli I, Patrizio A, Galdiero MR, Baldini E, Ulisse S, Marone G, Antonelli A. Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. *Int J Mol Sci.* 2019 May;20(10). pii: E2560.
170. Ferrari SM, Fallahi P, Elia G, Ragusa F, Ruffilli I, Paparo SR, Antonelli A. Thyroid autoimmune disorders and cancer. *Semin Cancer Biol.* 2020 Aug;64:135-146. doi: 10.1016/j.semcancer.2019.05.019.
171. Antonelli A, Ferrari SM, Elia G, Patrizio A, Fallahi P. Metastases free thyroid cancer patients harbouring TERT mutations may benefit from a more intensive treatment and follow-up. *Gland Surg.* 2019 Jun;8(3):298-300.
172. Varricchi G, Loffredo S, Marone G, Modestino L, Fallahi P, Ferrari SM, de Paulis A, Antonelli A, Galdiero MR. The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition. *Int J Mol Sci.* 2019 Aug;20(16). pii: E3934.
173. Ferrari SM, Fallahi P, Ruffilli I, Elia G, Ragusa F, Paparo SR, Patrizio A, Mazzi V, Colaci M, Giuggioli D, Ferri C, Antonelli A. Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C? *J Immunol Res.* 2019 Aug;2019:5878960.
174. Ferrari SM, Antonelli A, Guidi P, Bernardeschi M, Scarcelli V, Fallahi P, Frenzilli G. Genotoxicity Evaluation of the Soybean Isoflavone Genistein in Human Papillary Thyroid Cancer Cells. Study of Its Potential Use in Thyroid Cancer Therapy. *Nutr Cancer.* 2019;71(8):1335-1344.
175. Ferrari SM, Fallahi P, Galdiero MR, Ruffilli I, Elia G, Ragusa F, Paparo SR, Patrizio A, Mazzi V, Varricchi G, Marone G, Antonelli A. Immune and Inflammatory Cells in Thyroid Cancer Microenvironment. *Int J Mol Sci.* 2019 Sep;20(18). pii: E4413.
176. Fallahi P, Ferrari SM, Elia G, Ragusa F, Paparo SR, Ruffilli I, Patrizio A, Materazzi G, Antonelli A. Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes. *Cancer Manag Res.* 2019 Aug;11:7893-7907.
177. Ragusa F, Fallahi P, Elia G, Gonnella D, Paparo SR, Giusti C, Churilov LP, Ferrari SM, Antonelli A. Hashimoto's thyroiditis: Epidemiology, pathogenesis, clinic and therapy. *Best Pract Res Clin Endocrinol Metab.* 2019;33(6):101367. doi:10.1016/j.beem.2019.101367
178. Ferrari SM, Fallahi P, Elia G, Ragusa F, Camastra S, Paparo SR, Giusti C, Gonnella D, Ruffilli I, Shoenfeld Y, Antonelli A. Novel therapies for thyroid autoimmune diseases: An update. *Best Pract Res Clin Endocrinol Metab.* 2020;34(1):101366. doi:10.1016/j.beem.2019.101366.
179. Fallahi P, Ferrari SM, Ragusa F, Ruffilli I, Elia G, Paparo SR, Antonelli A. Th1 chemokines in autoimmune endocrine disorders. *J Clin Endocrinol Metab.* 2020 Apr 1;105(4):dgz289. doi: 10.1210/clinem/dgz289.
180. Elia G, Ferrari SM, Galdiero MR, et al. New insight in endocrine-related adverse events associated to immune checkpoint blockade. *Best Pract Res Clin Endocrinol Metab.* 2020;34(1):101370. doi:10.1016/j.beem.2019.101370.
181. Antonelli A, Fallahi P, Elia G, et al. Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. *Best Pract Res Clin Endocrinol Metab.* 2020;34(1):101388. doi:10.1016/j.beem.2020.101388.
182. Benvenga S, Elia G, Ragusa F, et al. Endocrine disruptors and thyroid autoimmunity. *Best Pract Res Clin Endocrinol Metab.* 2020;34(1):101377. doi:10.1016/j.beem.2020.101377.
183. Benvenga S, Ferrari SM, Elia G, et al. Nutraceuticals in Thyroidology: A Review of in Vitro, and in Vivo Animal Studies. *Nutrients.* 2020;12(5):1337. Published 2020 May 8. doi:10.3390/nu12051337.
184. Fallahi P, Ferrari SM, Elia G, et al. Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin [published online ahead of print, 2020 Jun 20]. *Semin Cancer Biol.* 2020;S1044-579X(20)30149-8. doi:10.1016/j.semcancer.2020.06.013.
185. Benvenga S, Marini HR, Micali A, et al. Protective Effects of Myo-Inositol and Selenium on Cadmium-Induced Thyroid Toxicity in Mice. *Nutrients.* 2020;12(5):1222. Published 2020 Apr 26. doi:10.3390/nu12051222.

H-index = 47 (Scopus)

Date
September 11th, 2020

Signature


In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal details contained in this document.